NCT07486713 2026-03-20Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel PharmaceuticalsPhase 4 Recruiting16 enrolled
NCT02719574 2025-06-26Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 MutationNovo Nordisk A/SPhase 1/2 Completed336 enrolled 48 charts 2 FDA